The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody‐Mediated Rejection Diagnostics: Strengths,Unmet Needs,and Future Directions |
| |
| Authors: | L Potena A Loupy A Zeevi E F Reed D Dragun N Reinsmoen R N Smith L West S Tebutt T Thum M Haas M Mengel P Revelo M Fedrigo J P Duong Van Huyen G J Berry |
| |
| Institution: | 1. Heart and Lung Transplant Program, University of Bologna, Academic Hospital S, Orsola‐Malpighi, Italy;2. Paris Translational Research Center for Organ Transplantation INSERM U970, Necker Hospital University Paris Descartes, Paris, France;3. University of Pittsburgh Medical Center, Pittsburgh, PA;4. Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA;5. Berlin Institute of Health and Department of Nephrology and Critical Care Medicine, Charité Universit?tsmedizin, Berlin, Germany;6. Cedars‐Sinai Medical Center, Los Angeles, CA;7. Pathology Department, Massachusetts General Hospital, Boston, MA;8. Alberta Transplant Institute and University of Alberta, Edmonton, Canada;9. Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada;10. IFB, Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany;11. Department of Pathology & Laboratory Medicine, Cedars‐Sinai Medical Center, Los Angeles, CA;12. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada;13. Intermountain Medical Center, University of Utah, Salt Lake City, UT;14. Department of Cardiac Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy;15. Department of Pathology, Stanford University, Stanford, CA |
| |
| Abstract: | The 13th Banff Conference on Allograft Pathology was held in Vancouver, British Columbia, Canada from October 5 to 10, 2015. The cardiac session was devoted to current diagnostic issues in heart transplantation with a focus on antibody‐mediated rejection (AMR) and small vessel arteriopathy. Specific topics included the strengths and limitations of the current rejection grading system, the central role of microvascular injury in AMR and approaches to semiquantitative assessment of histopathologic and immunophenotypic indicators, the role of AMR in the development of cardiac allograft vasculopathy, the important role of serologic antibody detection in the management of transplant recipients, and the potential application of new molecular approaches to the elucidation of the pathophysiology of AMR and potential for improving the current diagnostic system. Herein we summarize the key points from the presentations, the comprehensive, open and wide‐ranging multidisciplinary discussion that was generated, and considerations for future endeavors. |
| |
| Keywords: | clinical research/practice heart transplantation/cardiology rejection rejection: antibody‐mediated (ABMR) rejection: subclinical translational research/science |
|
|
